@sbrtmemes @_ShankarSiva Great question! Curious about what our fearless leader Shankar has to say, but here is provocative data from ORIOLE on the subject "Total consolidation of PSMA radiotracer-avid disease decreased the risk of new lesions at 6 months
RT @NicholasZaorsky: A few examples of the success of radiotherapy to the primary and to metastases: https://t.co/MO6sAAMLFA @PCaParker @P…
RT @NicholasZaorsky: A few examples of the success of radiotherapy to the primary and to metastases: https://t.co/MO6sAAMLFA @PCaParker @P…
RT @NicholasZaorsky: A few examples of the success of radiotherapy to the primary and to metastases: https://t.co/MO6sAAMLFA @PCaParker @P…
A few examples of the success of radiotherapy to the primary and to metastases: https://t.co/MO6sAAMLFA @PCaParker @Prof_Nick_James @TheLancetOncol https://t.co/T4qB6rFDrt @piet_ost @ASCO https://t.co/E1cGtLWRiR @JAMAOnc https://t.co/ukdbKGvNbn @Cha
The ORIOLE study evaluates stereotactic RT for men with oligometastatic prostate cancer. SBRT improves outcomes vs observation. https://t.co/xwWBU8k7r3 Updated results coming soon. SBRT seems to benefit pts w and w/o high risk mutations. https://t.co/PHcC
@RadOnc_AI Important to note that, while important, Lu-PSMA-617 is indicted for mCRPC and unlikely to be curative. SABR for oligomets (ORIOLE) has been investigated in mHSPC. Different patient population with different biology at play. https://t.co/J5jvt
@ARRO_org @NRGonc @rtdess @DrSpratticus @PCaParker 5. Metastatic prostate: treat the mets? STOMP https://t.co/2fdDxNHWPq @piet_ost ORIOLE https://t.co/E1cGtLWRiR I know this is >5, but they're too good to not mention :-)
RT @adelapoite: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomiz…
@scserendipity1 @piet_ost @ChrisSweens1 @matthewdeek @Movember @ProBioTrial @BramDL @okelidokeli @DrSpratticus @DrMLChua @AzadOncology Yes. But we sure need more data. https://t.co/JwNCnuib9l
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerThe ORIOLE: Phase 2 Randomized Clinical Trial. https://t.co/swmzendtxR
Clinical trial with metastatic #prostatecancer patients finds stereotactic radiation reduces cancer progression better than observation alone. https://t.co/1mmU4uDRoX
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network https://t.co/sVGh2JOIPw
RT @DrFRodriguezCov: En este ensayo clínico aleatorizado fase 2 de 54 hombres, la progresión de la enfermedad a los 6 meses ocurrió en 19%…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
RT @ManzoZurita: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomi…
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network https://t.co/SQgt10U2Gp
RT @DrFRodriguezCov: En este ensayo clínico aleatorizado fase 2 de 54 hombres, la progresión de la enfermedad a los 6 meses ocurrió en 19%…
RT @DrFRodriguezCov: En este ensayo clínico aleatorizado fase 2 de 54 hombres, la progresión de la enfermedad a los 6 meses ocurrió en 19%…
RT @DrFRodriguezCov: En este ensayo clínico aleatorizado fase 2 de 54 hombres, la progresión de la enfermedad a los 6 meses ocurrió en 19%…
En este ensayo clínico aleatorizado fase 2 de 54 hombres, la progresión de la enfermedad a los 6 meses ocurrió en 19% de participantes tratados con RT ablativa estereotáctica (SABR) y en 61% de los que sólo fueron vigilados https://t.co/IjbbD6uazo
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @SCIDirector: SCI members @AshAlizadeh and @max_diehn found that stereotactic ablative radiotherapy is a promising treatment for men wit…
SCI members @AshAlizadeh and @max_diehn found that stereotactic ablative radiotherapy is a promising treatment for men with recurrent hormone-sensitive oligometastatic #prostatecancer who wish to delay initiation of androgen deprivation therapy. https://t.
RT @williamyshi: The phase II ORIOLE trial is out today! Great work by Phuoc Tran and Ryan Phillips from Johns Hopkins demonstrating the ut…
RT @JAMAOnc: ORIOLE: compared to observation, stereotactic radiation delays progression in oligometastatic prostate cancer and induces a sy…
RT @JAMAOnc: ORIOLE: compared to observation, stereotactic radiation delays progression in oligometastatic prostate cancer and induces a sy…
RT @JAMAOnc: ORIOLE: compared to observation, stereotactic radiation delays progression in oligometastatic prostate cancer and induces a sy…
RT @JAMAOnc: ORIOLE: compared to observation, stereotactic radiation delays progression in oligometastatic prostate cancer and induces a sy…
ORIOLE: compared to observation, stereotactic radiation delays progression in oligometastatic prostate cancer and induces a systemic immune response. #VisualAbstract https://t.co/cC7J2xDQgZ
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network Great work! https://t.co/dwSvc0tF73
RT @b_fischervaluck: Important study! Great work #sbrt Observation vs Stereotactic Ablative Radiation for Oligometastatic…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @b_fischervaluck: Important study! Great work #sbrt Observation vs Stereotactic Ablative Radiation for Oligometastatic…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @b_fischervaluck: Important study! Great work #sbrt Observation vs Stereotactic Ablative Radiation for Oligometastatic…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @b_fischervaluck: Important study! Great work #sbrt Observation vs Stereotactic Ablative Radiation for Oligometastatic…
Important study! Great work #sbrt Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer https://t.co/4NpTruae5P
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @Rad_Nation: Promising trial in prostate cancer #radonc
Congrats. Fantastic study!
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
Promising trial in prostate cancer #radonc
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
Very interesting study . Unfortunately high drop out rate leaving only 18 patients in control arm. But encouraging for larger trials. The best thing would be to put every patient which receives non evidence based treatment in a trial.... #prostatecancer @D
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @MeritxellMolla: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Rand…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @jamesbyu: ORIOLE study from Dr. Phuoc Tran and team out in JAMA Onc showing benefit to treatment of PSMA-PET defined oligometastatic ca…
RT @MeritxellMolla: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Rand…
RT @MeritxellMolla: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Rand…
RT @MeritxellMolla: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Rand…